The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

Despite being given a cruel, short death sentence, this Noosa father-of-three refuses to give up and graciously says his ...

A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

At data cutoff, there was a 9% rate of grade 3 or higher treatment-related adverse ... drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer. J&J.

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

The Food and Drug Administration regulates food dyes. These are the food additives that add a rainbow of colors to many processed foods. Two types of synthetic red food dyes have been under ...

In 2020 AMPLITUDE set out with the ambition of developing and testing new technologies that advance bladder cancer diagnosis and treatment by utilizing the third biological window for deeper, ...

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Raritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S.